منابع مشابه
The hackathon model to spur innovation around global mHealth.
The challenge of providing quality healthcare to underserved populations in low- and middle-income countries (LMICs) has attracted increasing attention from information and communication technology (ICT) professionals interested in providing societal impact through their work. Sana is an organisation hosted at the Institute for Medical Engineering and Science at the Massachusetts Institute of T...
متن کاملDo Organizational Incentives Spur Innovation?
To date, we have only partially begun to develop an understanding of the channels through which innovation is facilitated within organizations. Although talented individuals are pivotal to supporting knowledge accumulation and renewal, they may be more willing to contribute new ideas if they expect to reap some of the gains that these ideas generate for the firm. In considering this perspective...
متن کاملDo General Managerial Skills Spur Innovation?
We show that firms with chief executive officers (CEOs) who gain general managerial skills over their lifetime work experience invest more in R&D and produce more patents. We address the potential endogenous CEO-firm matching bias using firmand CEOfixed effects and variation in the enforceability of non-compete agreements across states and over time during the CEO’s career. Our findings suggest...
متن کاملBioeconomy and the global economy: industrial policies and bio-innovation
The last decades have witnessed major growth in the bioeconomy. Emergence of the bioeconomy as a broad, creative and rapidly expanding part of the global economy coincides with the maturation of the established drug discovery system. This paper presents research evidence focused on the relationships between changes in the bioeconomy and changes in the global economy. It argues that new forms of...
متن کاملPatents as a Spur to Subsequent Innovation? Evidence from Pharmaceuticals
This paper examines how an incumbent’s patent protection acts as an implicit subsidy toward non-infringing substitutes. I analyze whether classes of pharmaceuticals whose first entrant has a longer period of market exclusivity (time between approval and generic entry) see more subsequent entry. Instrumenting for exclusivity using plausibly exogenous delays in the development process, I find tha...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Joule
سال: 2019
ISSN: 2542-4351
DOI: 10.1016/j.joule.2019.03.002